[email protected] +357 96 030922 Contact Us | FAQ |
Advanced search

VPAResearch: Market Research Reports

VPA Research is one of the global pharmaceutical companies specialized in analysis of clinical trials. We provide leading insights into global Pharma products, pipeline research, companies and drugs markets.

Publications found: 61,963
Sort by:

Measles R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Measles Pipeline Overview The Q4 Measles pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Measles...

October 2020 54 pages

Meningitis R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Meningitis Pipeline Overview The Q4 Meningitis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for M...

October 2020 64 pages

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline Overview The Q4 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline report is part of the VPA 110 Infectio...

October 2020 54 pages

Microscopic Polyangiitis (MPA) R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Microscopic Polyangiitis (MPA) Pipeline Overview The Q4 Microscopic Polyangiitis (MPA) pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipel...

October 2020 42 pages

Middle East Respiratory Syndrome (MERS) R&D Pipeline Analysis Report, Q4 2020

 US$ 1,979.00

Middle East Respiratory Syndrome (MERS) Pipeline Overview The Q4 Middle East Respiratory Syndrome (MERS) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly revi...

October 2020 104 pages

Mumps R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Mumps Pipeline Overview The Q4 Mumps pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Mumps, prov...

October 2020 40 pages

Myasthenia Gravis R&D Pipeline Analysis Report, Q4 2020

 US$ 1,979.00

Myasthenia Gravis Pipeline Overview The Q4 Myasthenia Gravis pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under develop...

October 2020 162 pages

Neisseria meningitidis Infections R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Neisseria meningitidis Infections Pipeline Overview The Q4 Neisseria meningitidis Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes...

October 2020 84 pages

Onychomycosis (Tinea Unguium) R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Onychomycosis (Tinea Unguium) Pipeline Overview The Q4 Onychomycosis (Tinea Unguium) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pip...

October 2020 76 pages

Osteomyelitis R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Osteomyelitis Pipeline Overview The Q4 Osteomyelitis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development...

October 2020 52 pages

Peanut Allergy R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Peanut Allergy Pipeline Overview The Q4 Peanut Allergy pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under development f...

October 2020 134 pages

Pemphigus Vulgaris R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Pemphigus Vulgaris Pipeline Overview The Q4 Pemphigus Vulgaris pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under devel...

October 2020 72 pages

Pertussis (Whooping Cough) R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Pertussis (Whooping Cough) Pipeline Overview The Q4 Pertussis (Whooping Cough) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline...

October 2020 112 pages

Phenylketonuria (PKU) R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Phenylketonuria (PKU) Pipeline Overview The Q4 Phenylketonuria (PKU) pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the pipeline of dru...

October 2020 81 pages

Pituitary ACTH Hypersecretion R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Pituitary ACTH Hypersecretion Pipeline Overview The Q4 Pituitary ACTH Hypersecretion pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the...

October 2020 43 pages

Plague R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Plague Pipeline Overview The Q4 Plague pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Plague, p...

October 2020 52 pages

Polio (Poliomyelitis) R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Polio (Poliomyelitis) Pipeline Overview The Q4 Polio (Poliomyelitis) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs u...

October 2020 101 pages

Pompe Disease R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Pompe Disease Pipeline Overview The Q4 Pompe Disease pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the pipeline of drugs under develop...

October 2020 101 pages

Post Menopausal Osteoporosis R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Post Menopausal Osteoporosis Pipeline Overview The Q4 Post Menopausal Osteoporosis pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the p...

October 2020 132 pages

Progressive Multifocal Leukoencephalopathy R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Progressive Multifocal Leukoencephalopathy Pipeline Overview The Q4 Progressive Multifocal Leukoencephalopathy pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterl...

October 2020 45 pages

Pyelonephritis R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Pyelonephritis Pipeline Overview The Q4 Pyelonephritis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under developme...

October 2020 81 pages

Rabies R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Rabies Pipeline Overview The Q4 Rabies pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Rabies, p...

October 2020 97 pages

Ragweed Pollen Allergy R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Ragweed Pollen Allergy Pipeline Overview The Q4 Ragweed Pollen Allergy pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs und...

October 2020 41 pages

Resistant Pseudomonas aeruginosa Infections R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Resistant Pseudomonas aeruginosa Infections Pipeline Overview The Q4 Resistant Pseudomonas aeruginosa Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarte...

October 2020 61 pages

Rhinovirus Infections R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Rhinovirus Infections Pipeline Overview The Q4 Rhinovirus Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs u...

October 2020 71 pages

Rotavirus Infections R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Rotavirus Infections Pipeline Overview The Q4 Rotavirus Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs und...

October 2020 58 pages

Rubella (German Measles) R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Rubella (German Measles) Pipeline Overview The Q4 Rubella (German Measles) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of d...

October 2020 52 pages

Schistosomiasis R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Schistosomiasis Pipeline Overview The Q4 Schistosomiasis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under develop...

October 2020 48 pages

Severe Acute Respiratory Syndrome (SARS) R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Severe Acute Respiratory Syndrome (SARS) Pipeline Overview The Q4 Severe Acute Respiratory Syndrome (SARS) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly re...

October 2020 131 pages

Sjogren Syndrome R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Sjogren Syndrome Pipeline Overview The Q4 Sjogren Syndrome pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under developme...

October 2020 147 pages

Smallpox R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Smallpox Pipeline Overview The Q4 Smallpox pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Small...

October 2020 64 pages

Streptococcus pyogenes Infections R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Streptococcus pyogenes Infections Pipeline Overview The Q4 Streptococcus pyogenes Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes...

October 2020 45 pages

Tetanus R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Tetanus Pipeline Overview The Q4 Tetanus pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Tetanus...

October 2020 132 pages

Tinea pedis (Athlete Foot) R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Tinea pedis (Athlete Foot) Pipeline Overview The Q4 Tinea pedis (Athlete Foot) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline...

October 2020 40 pages

Toxoplasmosis R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Toxoplasmosis Pipeline Overview The Q4 Toxoplasmosis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development...

October 2020 30 pages

Tularaemia R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Tularaemia Pipeline Overview The Q4 Tularaemia pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for T...

October 2020 45 pages

Typhoid Fever R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Typhoid Fever Pipeline Overview The Q4 Typhoid Fever pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development...

October 2020 61 pages

Vancomycin-Resistant Enterococcus faecium Infections R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Vancomycin-Resistant Enterococcus faecium Infections Pipeline Overview The Q4 Vancomycin-Resistant Enterococcus faecium Infections pipeline report is part of the VPA 110 Infectious Disease pipeline se...

October 2020 103 pages

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Pipeline Overview The Q4 Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections pipeline report is part of the VPA 110 Infectious Dis...

October 2020 61 pages

Ventilator Associated Pneumonia (VAP) R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Ventilator Associated Pneumonia (VAP) Pipeline Overview The Q4 Ventilator Associated Pneumonia (VAP) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review d...

October 2020 126 pages

Warts R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Warts Pipeline Overview The Q4 Warts pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Warts, prov...

October 2020 108 pages

West Nile Virus Infections R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

West Nile Virus Infections Pipeline Overview The Q4 West Nile Virus Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline...

October 2020 63 pages

Western Equine Encephalitis R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Western Equine Encephalitis Pipeline Overview The Q4 Western Equine Encephalitis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipelin...

October 2020 30 pages

Yellow Fever R&D Pipeline Analysis Report, Q4 2020

 US$ 1,529.00

Yellow Fever Pipeline Overview The Q4 Yellow Fever pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development f...

October 2020 63 pages

2020 COVID-19 Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

 US$ 2,159.00

Report Description The September updated COVID-19 clinical trials report presents a comprehensive 1800 page analysis on all clinical trials across 96 countries worldwide. The report provides phase wis...

September 2020 1800 pages

COVID-19 Therapy and Vaccine Drug Pipeline Market Report- September 2020 Update

 US$ 2,609.00

The September 2020 updated COVID-19 report identifies 440 companies investing in therapy and vaccination products. Around 24 companies have advanced their products into Phase 3 and around 15 companies...

September 2020 512 pages

COVID-19 Therapy and Vaccine Drug Pipeline and Clinical Trials Report- September 2020 Update

 US$ 3,825.00

COVID-19 Pipeline Analysis The September 2020 updated COVID-19 report identifies 440 companies investing in therapy and vaccination products. Around 24 companies have advanced their products into Phas...

September 2020 2300 pages

Acne Vulgaris pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

 US$ 1,439.00

2020 Acne Vulgaris PIPELINE HIGHLIGHTS Acne Vulgaris is one of the widely researched conditions during 2020 with 42 companies actively focusing on realizing pipeline’s potential. Development of Acne V...

July 2020 210 pages

Acromegaly pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

 US$ 1,439.00

2020 Acromegaly PIPELINE HIGHLIGHTS Acromegaly is one of the widely researched conditions during 2020 with 22 companies actively focusing on realizing pipeline’s potential. Development of Acromegaly m...

July 2020 96 pages

Actinic Keratosis pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

 US$ 1,439.00

2020 Actinic Keratosis PIPELINE HIGHLIGHTS Actinic Keratosis is one of the widely researched conditions during 2020 with 10 companies actively focusing on realizing pipeline’s potential. Development o...

July 2020 59 pages

Filters

Clear all

Search

Categories

217
134
126
109
104
94
87
86
80
67
62
54
50
47
47
45
43
42
40
36
33
32
27
25
23
22
21
20
20
20
17
17
17
17
16
16
14
14
14
12
12
11
11
11
11
11
10
9
9
8
7
7
7
7
7
6
6
6
6
6
6
6
5
5
5
5
4
4
4
4
4
4
4
4
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1,427
60
12,919
1,221
3
4,407
24
19
12,565
2,526
15,114
303
7,118
1
1,232
722

Publishers

61,963

Regions

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
61,926

Price

—

Date

—

Pages

—

Offers